TY  - JOUR

T1  - Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial

JO  - The Lancet Oncology

UR  - http://dx.doi.org/10.1016/s1470-2045(22)00793-8

PY  - 2023/02/13

AU  - Brown JE

AU  - Royle K-L

AU  - Gregory W

AU  - Ralph C

AU  - Maraveyas A

AU  - Din O

AU  - Eisen T

AU  - Nathan P

AU  - Powles T

AU  - Griffiths R

AU  - Jones R et al

ED  - 

DO  - DOI: 10.1016/s1470-2045(22)00793-8

PB  - Elsevier BV

VL  - 24

IS  - 3

SP  - 213

EP  - 227

Y2  - 2024/12/21

ER  -